Increased Risk of Persistent Glucose Disorders After Control of Acromegaly
| Autor: | Claire Rochette, Thierry Brue, Henry Dufour, Thomas Graillon, Frédérique Albarel, I. Morange, Frederic Castinetti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
hypertension Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism pituitary adenoma 030204 cardiovascular system & hematology somatostatin Gastroenterology surgery 03 medical and health sciences 0302 clinical medicine Pituitary adenoma Diabetes mellitus Internal medicine Epidemiology Acromegaly Medicine education Clinical Research Articles education.field_of_study diabetes business.industry Hypertriglyceridemia Pituitary and Neuroendocrinology medicine.disease Comorbidity Endocrinology Somatostatin acromegaly business |
| Zdroj: | Journal of the Endocrine Society |
| ISSN: | 2472-1972 |
| Popis: | Purpose: Combining surgery and medical treatments allows the control of growth hormone hypersecretion in 80% of cases. Our objective was to determine the rate of acromegaly comorbidities once hypersecretion of growth hormone is controlled. Methods: Our retrospective monocentric study was based on 130 patients followed on a regular basis, with acromegaly controlled by medical treatments or cured by surgery or radiation technique. Our main outcome measures were the prevalence of major metabolic complications of acromegaly (diabetes, hypertension, low-density lipoprotein cholesterol, triglycerides) at diagnosis and last follow-up in comparison with French epidemiological data. Results: As expected, controlling hypersecretion significantly improved the metabolic complications of acromegaly. However, the proportion of patients having at least one metabolic complication of acromegaly at last follow-up (mean, 72 months after remission) was 27% for altered glucose tolerance or diabetes, 39% for hypertension, 34.3% for hypercholesterolemia, and 13.3% for hypertriglyceridemia. Interestingly, our data showed that diabetes was the only comorbidity different with a higher prevalence in patients in remission versus a general population of a similar median age (21.6% vs 6.9%, respectively). Conclusions: The follow-up of glucose disorders needs to be maintained on a long-term basis in patients controlled for acromegaly. Comorbidities of acromegaly can persist for several years despite controlled GH levels. Diabetes should be particularly followed and treated independently of the final GH status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|